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t is essential that the medical profession play a central role
n critically evaluating the evidence related to drugs, devices,
nd procedures for the detection, management, or preven-
ion of disease. Properly applied, rigorous, expert analysis of
he available data documenting absolute and relative bene-
ts and risks of these therapies and procedures can improve
he effectiveness of care, optimize patient outcomes, and
avorably affect the cost of care by focusing resources on the
ost effective strategies. One important use of such data is
he production of clinical practice guidelines that, in turn,
an provide a foundation for a variety of other applications,
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ecision support tools, and quality improvement tools.
The American College of Cardiology Foundation
ACCF) and the American Heart Association (AHA) have
ointly engaged in the production of guidelines in the area of
ardiovascular disease since 1980. The ACCF/AHA Task
orce on Practice Guidelines (Task Force) is charged with
eveloping, updating, and revising practice guidelines for
ardiovascular diseases and procedures, and the Task Force
irects and oversees this effort. Writing committees are
harged with assessing the evidence as an independent
roup of authors to develop, update, or revise recommen-
ations for clinical practice.
Experts in the subject under consideration have been
elected from both organizations to examine subject-specific
ata and write guidelines in partnership with representatives
rom other medical practitioner and specialty groups. Writ-
ng committees are specifically charged to perform a formal
iterature review; weigh the strength of evidence for or
gainst particular tests, treatments, or procedures; and
nclude estimates of expected health outcomes where data
xist. Patient-specific modifiers, comorbidities, and issues of
atient preference that may influence the choice of tests or
herapies are considered. When available, information from
tudies on cost is considered, but data on efficacy and clinical
utcomes constitute the primary basis for recommendations
n these guidelines.
In analyzing the data and developing recommendations
nd supporting text, the writing committee used evidence-
ased methodologies developed by the Task Force that are
escribed elsewhere (1). The committee reviewed and
anked evidence supporting current recommendations, with
he weight of evidence ranked as Level A if the data were
erived from multiple randomized clinical trials or meta-
nalyses. The committee ranked available evidence as Level
when data were derived from a single randomized trial or
onrandomized studies. Evidence was ranked as Level C
hen the primary source of the recommendation was
onsensus opinion, case studies, or standard of care. In the
arrative portions of these guidelines, evidence is generally
resented in chronological order of development. Studies
re identified as observational, retrospective, prospective, or
andomized when appropriate. For certain conditions for
hich inadequate data are available, recommendations are
ased on expert consensus and clinical experience and
anked as Level C. An example is the use of penicillin for
neumococcal pneumonia, where there are no randomized
rials and treatment is based on clinical experience. When
ecommendations at Level C are supported by historical
linical data, appropriate references (including clinical re-
iews) are cited if available. For issues where sparse data are
vailable, a survey of current practice among the clinicians
n the writing committee was the basis for Level C
ecommendations and no references are cited. The schema
or Classification of Recommendations (COR) and Level of rvidence (LOE) is summarized in Table 1, which also
llustrates how the grading system provides an estimate of
he size as well as the certainty of the treatment effect. A
ew addition to the ACCF/AHA methodology is a sepa-
ation of the Class III recommendations to delineate
hether the recommendation is determined to be of “no
enefit” or associated with “harm” to the patient. In addi-
ion, in view of the increasing number of comparative effec-
iveness studies, comparator verbs and suggested phrases for
riting recommendations for the comparative effectiveness of
ne treatment/strategy with respect to another for COR I and
Ia, LOE A or B only, have been added.
The Task Force makes every effort to avoid actual,
otential, or perceived conflicts of interest that may arise
s a result of industry relationships or personal interests
mong the writing committee. Specifically, all members
f the writing committee, as well as peer reviewers of the
ocument, are asked to disclose all relevant relationships
nd those existing 24 months before initiation of the
riting effort. All guideline recommendations require a
onfidential vote by the writing committee and must be
pproved by a consensus of the members voting. Mem-
ers who were recused from voting are noted on the title
age of this document and in Appendix 1. Members must
ecuse themselves from voting on any recommendation to
hich their relationships with industry and other entities
RWI) applies. Any writing committee member who devel-
ps new RWI during his or her tenure is required to notify
uideline staff in writing. These statements are reviewed by
he Task Force and all members during each conference call
nd meeting of the writing committee and are updated as
hanges occur. For detailed information about guideline
olicies and procedures, please refer to the ACCF/AHA
ethodology and policies manual (1). Authors’ and peer
eviewers’ RWI pertinent to this guideline are disclosed in
ppendixes 1 and 2, respectively. In addition, to ensure
omplete transparency, writing committee members’ com-
rehensive disclosure information—including RWI not perti-
ent to this document—is available online as a supplement
o this document. Disclosure information for the ACCF/
HA Task Force on Practice Guidelines is also available
nline at www.cardiosource.org/ACC/About-ACC/
eadership/Guidelines-and-Documents-Task-Forces.aspx.
he work of the writing committee was supported exclu-
ively by the ACCF and AHA without commercial support.
riting committee members volunteered their time for this
ffort.
The ACCF/AHA practice guidelines address patient
opulations (and health care providers) residing in North
merica. As such, drugs that are not currently available in
orth America are discussed in the text without a specific
OR. For studies performed in large numbers of subjects
utside of North America, each writing committee re-
iews the potential impact of different practice patterns
nd patient populations on the treatment effect and the
elevance to the ACCF/AHA target population to de-
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ecommendation.
The ACCF/AHA practice guidelines are intended to
ssist health care providers in clinical decision making by
escribing a range of generally acceptable approaches to the
iagnosis, management, and prevention of specific diseases
r conditions. These practice guidelines represent a consen-
us of expert opinion after a thorough and systematic review
f the available current scientific evidence and are intended
o improve patient care. The guidelines attempt to define
ractices that meet the needs of most patients in most
ituations. The ultimate judgment regarding care of a
able 1. Applying Classification of Recommendations and Leve
■ 
Data available from clinical trials or registries about the usefulness/efficacy in different subpop
ailure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply th
end themselves to clinical trials. Even though randomized trials are not available, there may be
†For comparative effectiveness recommendations (Class I and IIa; Level of Evidence A and
reatments or strategies being evaluated.articular patient must be made by the health care provider rnd patient in light of all the circumstances presented by
hat patient. Thus, there are circumstances in which devi-
tions from these guidelines may be appropriate. Clinical
ecision making should consider the quality and availability
f expertise in the area where care is provided. When these
uidelines are used as the basis for regulatory or payer
ecisions, the goal should be improvement in quality of care.
he Task Force recognizes that situations arise in which
dditional data are needed to better inform patient care;
hese areas will be identified within each respective guide-
ine when appropriate.
Prescribed courses of treatment in accordance with these
vidence
, such as gender, age, history of diabetes, history of prior myocardial infarction, history of heart
ecommendation is weak. Many important clinical questions addressed in the guidelines do not
clear clinical consensus that a particular test or therapy is useful or effective.
, studies that support the use of comparator verbs should involve direct comparisons of thel of E
ulations
at the r
a veryecommendations are effective only if they are followed.
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CV Risk Guideline: Executive Summary December 14/21, 2010:2182–99ecause lack of patient understanding and adherence may
dversely affect outcomes, physicians and other health care
roviders should make every effort to engage the patient’s
ctive participation in prescribed medical regimens and
ifestyles.
The guidelines will be reviewed annually by the Task
orce and considered current until they are updated, revised,
r withdrawn from distribution. The full-text guideline is
-published in the Journal of the American College of Cardi-
logy, Circulation, and the Journal of Cardiovascular Com-
uted Tomography.
Alice K. Jacobs, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines
. Introduction
.1. Methodology and Evidence Review
he recommendations listed in this document are, when-
ver possible, evidence based. An extensive evidence
eview was conducted for the period beginning March
008 through April 2010. Searches were limited to
tudies, reviews, and other evidence conducted in human
ubjects and published in English. Key search words
ncluded, but were not limited to, African Americans,
sian Americans, albuminuria, asymptomatic, asymptomatic
creening and brachial artery reactivity, atherosclerosis im-
ging, atrial fibrillation, brachial artery testing for athero-
clerosis, calibration, cardiac tomography, compliance, carotid
ntima-media thickness, coronary calcium, coronary computed
omography angiography, C-reactive protein (CRP), detec-
ion of subclinical atherosclerosis, discrimination, endothelial
unction, family history, flow-mediated dilation, genetics,
enetic screening, guidelines, Hispanic Americans, hemoglo-
in A, glycosylated, meta-analysis, Mexican Americans, myo-
ardial perfusion imaging (MPI), noninvasive testing, nonin-
asive testing and type 2 diabetes, outcomes, patient compliance,
eripheral arterial tonometry, peripheral tonometry and athero-
clerosis, lipoprotein-associated phospholipase A2, primary pre-
ention of coronary artery disease, proteinuria, cardiovascular
isk, risk scoring, receiver operating characteristics curve, screen-
ng for brachial artery reactivity, stress echocardiography, sub-
linical atherosclerosis, subclinical and Framingham, subclinical
nd Multi-Ethnic Study of Atherosclerosis (MESA), and type 2
iabetes. Additionally, the writing committee reviewed doc-
ments related to the subject matter previously published by
he ACCF and AHA, American Diabetes Association,
uropean Society of Cardiology, and the Joint National
ommittee on Prevention, Detection, Evaluation, and
reatment of High Blood Pressure (JNC) 7. References
elected and published in this document are representative
nd not all-inclusive.
To provide clinicians with a comprehensive set of data,
henever deemed appropriate or when published in the
rticle, data from the clinical trial will be used to calculate
he absolute risk difference and number needed to treat or narm; data related to the relative treatment effects will also
e provided, such as odds ratio, relative risk, hazard ratio, or
ncidence rate ratio, along with confidence interval when
vailable.
The focus of this guideline is the initial assessment of the
pparently healthy adult for risk of developing cardiovascu-
ar events associated with atherosclerotic vascular disease.
he goal of this early assessment of cardiovascular risk in an
symptomatic individual is to provide the foundation for
argeted preventive efforts based on that individual’s pre-
icted risk. It is based on the long-standing concept of
argeting the intensity of drug treatment interventions to
he severity of the patient’s risk (2). This clinical approach
erves as a complement to the population approach to
revention of cardiovascular disease (CVD), in which
opulation-wide strategies are used regardless of an individ-
al’s risk.
This guideline pertains to initial assessment of cardiovas-
ular risk in the asymptomatic adult. Although there is no
lear age cut point for defining the onset of risk for CVD,
levated risk factor levels and subclinical abnormalities can
e detected in adolescents as well as young adults. To
aximize the benefits of prevention-oriented interventions,
specially those involving lifestyle changes, the writing
ommittee advises that these guidelines be applied in
symptomatic persons beginning at age 20 years. The
riting committee recognizes that the decision about a
tarting point is an arbitrary one.
This document specifically excludes from consideration
atients with a diagnosis of CVD or a coronary event, for
xample, angina or anginal equivalent, myocardial infarc-
ion, or revascularization with percutaneous coronary inter-
ention or coronary artery bypass graft surgery. It also
xcludes testing for patients with known peripheral artery
isease and cerebral vascular disease. This guideline is not
ntended to replace other sources of information on cardio-
ascular risk assessment in specific disease groups or in
igher-risk groups such as those with known hypertension
r diabetes who are receiving treatment.
.2. Organization of the Writing Committee
he committee was composed of physicians and other
xperts in the field of cardiology. The committee included
epresentatives from the American Society of Echocardiog-
aphy, American Society of Nuclear Cardiology, Society of
therosclerosis Imaging and Prevention, Society for Car-
iovascular Angiography and Interventions, Society of
ardiovascular Computed Tomography, and Society for
ardiovascular Magnetic Resonance.
.3. Document Review and Approval
his document was reviewed by 2 outside reviewers nomi-
ated by the ACCF and 2 outside reviewers nominated by
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December 14/21, 2010:2182–99 CV Risk Guideline: Executive Summaryhe AHA, as well as 2 reviewers each from the American
ociety of Echocardiography, American Society of Nuclear
ardiology, Society of Atherosclerosis Imaging and Preven-
ion, Society for Cardiovascular Angiography and Interven-
ions, Society of Cardiovascular Computed Tomography,
nd Society for Cardiovascular Magnetic Resonance, and 23
ndividual content reviewers (including members from the
CCF Appropriate Use Criteria Task Force, ACCF Car-
iac Catheterization Committee, ACCF Imaging Council,
nd ACCF Prevention of Cardiovascular Disease Commit-
ee). All reviewer RWI information was collected and
istributed to the writing committee and is published in this
ocument (Appendix 2).
This document was approved for publication by the
overning bodies of the ACCF and AHA and endorsed by
he American Society of Echocardiography, American So-
iety of Nuclear Cardiology, Society of Atherosclerosis
maging and Prevention, Society for Cardiovascular An-
iography and Interventions, Society of Cardiovascular
omputed Tomography, and Society for Cardiovascular
agnetic Resonance.
.4. Magnitude of the Problem of
ardiovascular Risk in Asymptomatic Adults
therosclerotic CVD is the leading cause of death for both
en and women in the United States (3). It is estimated
hat if all forms of major CVD were eliminated, life
xpectancy would rise by almost 7 years (4). Coronary heart
isease (CHD) has a long asymptomatic latent period,
hich provides an opportunity for early preventive interven-
ions. One aim of this guideline is to provide an evidence-
ased approach to risk assessment in an effort to lower this
igh burden of coronary deaths in asymptomatic adults.
.5. Assessing the Prognostic Value of
isk Factors and Risk Markers
any risk factors have been proposed as predictors of CHD
5,6). New risk factors or markers are frequently identified
nd evaluated as potential additions to standard risk assess-
ent strategies. The AHA has published a scientific state-
ent on appropriate methods for evaluating the predictive
alue of new risk factors or risk markers (7). The scientific
tatement endorsed previously published guidelines for
roper reporting of observational studies in epidemiology
8) but also went beyond those guidelines to specifically
ddress criteria for evaluation of established and “new” risk
arkers.
For any new risk marker to be considered a useful
andidate for risk prediction, it must, at the very least, have
n independent statistical association with risk after ac-
ounting for established readily available and inexpensive
isk markers. This independent statistical association should
e based on studies that include large numbers of outcome
vents. Traditionally, reports of novel risk markers have only sone this far, reporting adjusted hazard ratios with confi-
ence intervals and p values (9). Although this level of basic
tatistical association is often regarded by researchers as
eaningful in prediction of a particular outcome of interest,
he AHA scientific statement called for considerably more
igorous assessments that include analysis of the calibration,
iscrimination, and reclassification of the predictive model
7). Many of the tests reviewed in this guideline fail to
rovide these more comprehensive measures of test evalua-
ion, and for this reason, many tests that are statistically
ssociated with clinical outcomes cannot be judged to be
seful beyond a standard risk assessment profile. In the
bsence of this evidence of “additive predictive informa-
ion,” the writing committee generally concluded that a new
isk marker was not ready for routine use in risk assessment.
Calibration and discrimination are 2 separate concepts
hat do not necessarily track with each other. Calibration
efers to the ability to correctly predict the proportion of
ubjects within any given group who will experience disease
vents. Among patients predicted to be at higher risk, there
ill be a higher number of events, whereas among patients
dentified as being at lower risk, there will be fewer events.
or example, if a diagnostic test or a multivariable model
plits patients into 3 groups with predicted risks of 5%, 10%,
nd 15% within each group, calibration would be considered
ood if in a separate group of cohorts with similar predicted
isks, the actual rates of events were close to 5%, 10%, and
5%. Calibration is best presented by displaying observed
ersus expected event rates across quantiles of predicted risk
or models that do and do not include the new risk marker.
Discrimination is a different concept that refers to the
robability of a diagnostic test or a risk prediction instru-
ent to distinguish between patients who are at higher
ompared with lower risk. For example, a clinician sees 2
andom patients, 1 of whom is ultimately destined to
xperience a clinical event. A diagnostic test or risk model
iscriminates well if it usually correctly predicts which of the
subjects is at higher risk for an event. Mathematically this
s described by calculating a C index or C statistic, param-
ters that are analogous to the area under the receiver
perating characteristics curve. These statistics define the
robability that a randomly selected person from the “af-
ected group” will have a higher test score than a randomly
elected person from the “nonaffected group.” A test with no
iscrimination would have a C statistic of 0.50 and a perfect
est would have a C statistic of 1.0. Throughout this
ocument, C statistic information is cited where available.
Some investigators have called for evaluating the number
f subjects reclassified into other risk categories based on
odels that include the new risk marker (10). One problem
ith this approach is that not all reclassification is neces-
arily clinically useful. If a patient is deemed to be at
ntermediate risk and is then reclassified as being at high or
ow risk, the clinician might find that information helpful. It
ay not be known, however, whether or not these reclas-
ifications are correct for individual subjects. Two new
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amely “net reclassification improvement” and “integrated
iscrimination improvement,” which provide quantitative
stimates of correct reclassifications (11). Correct reclassifi-
ations are associated with higher predicted risks for cases
nd lower predicted risks for noncases.
.6. Usefulness in Motivating Patients or
uiding Therapy
atients deemed to be at low risk for clinical events are
nlikely to gain substantial benefits from pharmaceutical
nterventions and therefore might best be managed with
ifestyle modifications. Conversely, patients deemed to be at
igh risk for events are more likely to benefit from phar-
acologic interventions and therefore are appropriate can-
idates for intensive risk factor modification efforts. Among
atients at intermediate risk, further testing may be indi-
ated to refine risks and assess the need for treatment.
.7. Economic Evaluation of Novel Risk Markers
he progressively rising costs of medical care have increased
nterest in documenting the economic effects of new tests
nd therapies. The most basic goal is to estimate the
conomic consequences of a decision to order a new test.
he ultimate goal is to determine whether performing the
est provides sufficient value to justify its use.
In general, testing strategies such as those assessed in this
ocument have not included evaluations of the costs and
ost-effectiveness of the tests. The writing committee was
enerally unable to find evidence to support the cost-
ffectiveness of any of the tests and testing approaches
iscussed here. Where exceptions were identified, cost-
able 2. Comparison of a Sample of Global Coronary and Cardi
Framingham SCORE
ample size 5,345 205,178 5,
ge (y) 30 to 74; M: 49 19 to 80; M: 46 35
ean follow-up (y) 12 13 10
isk factors
considered
Age, sex, total cholesterol,
HDL cholesterol,
smoking, systolic blood
pressure,
antihypertensive
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cholesterol ratio,
smoking,
systolic blood
pressure
Ag
ndpoints CHD (MI and CHD death) Fatal CHD Fa
RLs for risk
calculators
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atpiii/calculator.
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pages/
welcome.aspx
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HD indicates coronary heart disease; CVD, cardiovascular disease; HbA1C, hemoglobin A1C; H
ean; MI, myocardial infarction; PROCAM, Münster Heart Study; and SCORE, Systematic Coronelated information is included.. Recommendation for Global Risk Scoring
LASS I
. Global risk scores (such as the Framingham Risk Score) that use
multiple traditional cardiovascular risk factors should be obtained for
risk assessment in all asymptomatic adults without a clinical history of
CHD. These scores are useful for combining individual risk factor
measurements into a single quantitative estimate of risk that can be
used to target preventive interventions (12). (Level of Evidence: B)
Table 2 summarizes a sample of published global risk
core instruments that take into account modifiable risk
arkers that are also appropriate evidence-based targets for
reventive interventions.
. Recommendation for Family History
LASS I
. Family history of atherothrombotic CVD should be obtained for
cardiovascular risk assessment in all asymptomatic adults (13,14).
(Level of Evidence: B)
. Recommendation for Genomic Testing
LASS III: NO BENEFIT
. Genotype testing for CHD risk assessment in asymptomatic adults
is not recommended (15,16). (Level of Evidence: B)
. Recommendation for Lipoprotein and
polipoprotein Assessments
LASS III: NO BENEFIT
. Measurement of lipid parameters, including lipoproteins, apoli-
cular Risk Scores
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in asymptomatic adults (17). (Level of Evidence: C)
. Recommendation for Measurement of
atriuretic Peptides
LASS III: NO BENEFIT
. Measurement of natriuretic peptides is not recommended for CHD
risk assessment in asymptomatic adults (18). (Level of Evidence: B)
. Recommendations for Measurement of
-Reactive Protein
LASS IIa
. In men 50 years of age or older or women 60 years of age or older
with low-density lipoprotein cholesterol less than 130mg/dL; not on
lipid-lowering, hormone replacement, or immunosuppressant ther-
apy; without clinical CHD, diabetes, chronic kidney disease, severe
inflammatory conditions, or contraindications to statins, measure-
ment of CRP can be useful in the selection of patients for statin
therapy (19). (Level of Evidence: B)
LASS IIb
. In asymptomatic intermediate-risk men 50 years of age or younger
or women 60 years of age or younger, measurement of CRPmay be
reasonable for cardiovascular risk assessment (14,20). (Level of
Evidence: B)
LASS III: NO BENEFIT
. In asymptomatic high-risk adults, measurement of CRP is not
recommended for cardiovascular risk assessment (21). (Level of
Evidence: B)
. In low-risk men younger than 50 years of age or women 60 years of
age or younger, measurement of CRP is not recommended for
cardiovascular risk assessment (14,20). (Level of Evidence: B)
. Recommendation for Measurement of
emoglobin A1C
LASS IIb
. Measurement of hemoglobin A1C may be reasonable for cardiovas-
cular risk assessment in asymptomatic adults without a diagnosis
of diabetes (22–27). (Level of Evidence: B)
. Recommendations for
esting for Microalbuminuria
LASS IIa
. In asymptomatic adults with hypertension or diabetes, urinalysis to
detect microalbuminuria is reasonable for cardiovascular risk as-
sessment (28–30). (Level of Evidence: B)
LASS IIb
. In asymptomatic adults at intermediate risk without hypertension or
diabetes, urinalysis to detect microalbuminuria might be reason-
able for cardiovascular risk assessment (31). (Level of Evidence: B)0. Recommendation for
ipoprotein-Associated Phospholipase A2
LASS IIb
. Lipoprotein-associated phospholipase A2 might be reasonable for
cardiovascular risk assessment in intermediate-risk asymptomatic
adults (32–35). (Level of Evidence: B)
1. Recommendations for
esting Electrocardiogram
LASS IIa
. A resting electrocardiogram (ECG) is reasonable for cardiovascular
risk assessment in asymptomatic adults with hypertension or dia-
betes (36,37). (Level of Evidence: C)
LASS IIb
. A resting ECG may be considered for cardiovascular risk assess-
ment in asymptomatic adults without hypertension or diabetes
(38–40). (Level of Evidence: C)
2. Recommendations for
ransthoracic Echocardiography
LASS IIb
. Echocardiography to detect left ventricular hypertrophy may be
considered for cardiovascular risk assessment in asymptomatic
adults with hypertension (41,42). (Level of Evidence: B)
LASS III: NO BENEFIT
. Echocardiography is not recommended for cardiovascular risk as-
sessment of CHD in asymptomatic adults without hypertension.
(Level of Evidence: C)
3. Recommendation for Measurement of
arotid Intima-Media Thickness
LASS IIa
. Measurement of carotid artery intima-media thickness is reason-
able for cardiovascular risk assessment in asymptomatic adults
at intermediate risk (43,44). Published recommendations
on required equipment, technical approach, and operator
training and experience for performance of the test must be
carefully followed to achieve high-quality results (44). (Level of
Evidence: B)
4. Recommendation for
rachial/Peripheral Flow-Mediated Dilation
LASS III: NO BENEFIT
. Peripheral arterial flow-mediated dilation studies are not recom-
mended for cardiovascular risk assessment in asymptomatic adults(45,46). (Level of Evidence: B)
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f Arterial Stiffness
LASS III: NO BENEFIT
. Measures of arterial stiffness outside of research settings are not
recommended for cardiovascular risk assessment in asymptomatic
adults. (Level of Evidence: C)
6. Recommendation for Measurement of
nkle-Brachial Index
LASS IIa
. Measurement of ankle-brachial index is reasonable for cardiovas-
cular risk assessment in asymptomatic adults at intermediate risk
(47). (Level of Evidence: B)
7. Recommendation for
xercise Electrocardiography
LASS IIb
. An exercise ECG may be considered for cardiovascular risk assess-
ment in intermediate-risk asymptomatic adults (including seden-
tary adults considering starting a vigorous exercise program), par-
ticularly when attention is paid to non-ECGmarkers such as exercise
capacity (48–50). (Level of Evidence: B)
8. Recommendation for
tress Echocardiography
LASS III: NO BENEFIT
. Stress echocardiography is not indicated for cardiovascular risk
assessment in low- or intermediate-risk asymptomatic adults. (Ex-
ercise or pharmacologic stress echocardiography is primarily used
for its role in advanced cardiac evaluation of symptoms suspected
of representing CHD and/or estimation of prognosis in patients with
known coronary artery disease or the assessment of patients with
known or suspected valvular heart disease.) (Level of Evidence: C)
9. Recommendations for
yocardial Perfusion Imaging
LASS IIb
. Stress MPI may be considered for advanced cardiovascular risk
assessment in asymptomatic adults with diabetes or asymptomatic
adults with a strong family history of CHD or when previous risk
assessment testing suggests high risk of CHD, such as a coronary
artery calcium (CAC) score of 400 or greater. (Level of Evidence: C)
LASS III: NO BENEFIT
. Stress MPI is not indicated for cardiovascular risk assessment in
low- or intermediate-risk asymptomatic adults (Exercise or pharma-
cologic stress MPI is primarily used and studied for its role in
advanced cardiac evaluation of symptoms suspected of represent-
ing CHD and/or estimation of prognosis in patients with known
coronary artery disease.) (51). (Level of Evidence: C)0. Recommendations for
alcium Scoring Methods
LASS IIa
. Measurement of CAC is reasonable for cardiovascular risk assess-
ment in asymptomatic adults at intermediate risk (10% to 20%
10-year risk) (52,53). (Level of Evidence: B)
LASS IIb
. Measurement of CAC may be reasonable for cardiovascular risk
assessment in persons at low to intermediate risk (6% to 10%
10-year risk) (53–55). (Level of Evidence: B)
LASS III: NO BENEFIT
. Persons at low risk (6% 10-year risk) should not undergo CAC
measurement for cardiovascular risk assessment (52,53,56). (Level
of Evidence: B)
1. Recommendation for Coronary
omputed Tomography Angiography
LASS III: NO BENEFIT
. Coronary computed tomography angiography is not recommended
for cardiovascular risk assessment in asymptomatic adults (57).
(Level of Evidence: C)
2. Recommendation for
agnetic Resonance Imaging of Plaque
LASS III: NO BENEFIT
. Magnetic resonance imaging for detection of vascular plaque is not
recommended for cardiovascular risk assessment in asymptomatic
adults. (Level of Evidence: C)
3. Recommendations for
atients With Diabetes Mellitus
LASS IIa
. In asymptomatic adults with diabetes, 40 years of age and older,
measurement of CAC is reasonable for cardiovascular risk assess-
ment (58–61). (Level of Evidence: B)
LASS IIb
. Measurement of hemoglobin A1C may be considered for cardiovas-
cular risk assessment in asymptomatic adults with diabetes (62).
(Level of Evidence: B)
. Stress MPI may be considered for advanced cardiovascular risk
assessment in asymptomatic adults with diabetes or when previous
risk assessment testing suggests a high risk of CHD, such as a CAC
score of 400 or greater. (Level of Evidence: C)
4. Recommendations for
pecial Considerations In Women
LASS I
. A global risk score should be obtained in all asymptomatic women
(14,63). (Level of Evidence: B)
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assessment in all asymptomatic women (13,14). (Level of Evidence: B)
5. Clinical Implications of Risk Assessment:
oncluding Comments
he assessment of risk for development of clinical manifes-
ations of atherosclerotic CVD is designed to aid the
linician in informed decision making about lifestyle and
harmacologic interventions to reduce such risk. Patients
re broadly categorized into low-, intermediate-, and high-
isk subsets, and level of intensity and type of treatments are
ased on these differing assessments of risk.
The initial step in risk assessment in individual patients
nvolves the ascertainment of a global risk score (Framing-
am, Reynolds, etc.) and the elucidation of a family history
f atherosclerotic CVD. These Class I recommendations,
hich are simple and inexpensive, determine subsequent
trategies to be undertaken. Persons at low risk do not
equire further testing for risk assessment, as more intensive
nterventions are considered unwarranted, and those already
ocumented to be at high risk (established CHD or coro-
ary risk equivalents) are already candidates for intensive
reventive interventions, so that added testing will not
rovide incremental benefit. rFor the intermediate-risk patient, this guideline should
elp the clinician select appropriate test modalities that can
urther define risk status. Tests classified as Class IIa are
hose shown to provide benefit that exceeds costs and risk.
election among these will vary with local availability and
xpertise, decisions regarding cost, and potential risks such
s radiation exposure, etc. Tests classified as Class IIb have
ess robust evidence for benefit but may prove helpful in
elected patients. Tests classified as Class III are not
ecommended for use in that there is no, or rather limited,
vidence of their benefit in incrementally adding to the
ssessment of risk; therefore, these tests fail to contribute to
hanges in the clinical approach to therapy. In addition, a
umber of Class III tests discussed in this guideline require
dditional efforts to standardize the measurement or make
he test more commonly available on a routine clinical basis.
urthermore, some of the Class III tests also pose potential
arm (radiation exposure or psychological distress in the
bsence of a defined treatment strategy) and are therefore to
e avoided for cardiovascular risk assessment purposes in the
symptomatic adult. Until additional research is accom-
lished to justify the addition of Class III tests, the writing
ommittee recommends against their use for cardiovascular
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